Next Article in Journal
Redox Regulation of Microvascular Permeability: IL-1β Potentiation of Bradykinin-Induced Permeability Is Prevented by Simvastatin
Next Article in Special Issue
Sitagliptin Modulates Oxidative, Nitrative and Halogenative Stress and Inflammatory Response in Rat Model of Hepatic Ischemia-Reperfusion
Previous Article in Journal
Antioxidant Activity of Flavonoids in LPS-Treated IPEC-J2 Porcine Intestinal Epithelial Cells and Their Antibacterial Effect against Bacteria of Swine Origin
Previous Article in Special Issue
Bariatric Surgery Normalizes Protein Glycoxidation and Nitrosative Stress in Morbidly Obese Patients
Commentary

Nitric Oxide (NO) and Duchenne Muscular Dystrophy: NO Way to Go?

1
Institute for Health and Sport, Victoria University, Melbourne 8001, Victoria, Australia
2
Australian Institute for Musculoskeletal Science, St Albans 3021, Victoria, Australia
3
Institut de Myologie, Sorbonne University, INSERM UMRS974 Paris, France
*
Author to whom correspondence should be addressed.
Antioxidants 2020, 9(12), 1268; https://doi.org/10.3390/antiox9121268
Received: 26 November 2020 / Accepted: 11 December 2020 / Published: 13 December 2020
(This article belongs to the Special Issue Oxidative-Nitrative Stress in Human Health and Disease)
The discordance between pre-clinical success and clinical failure of treatment options for Duchenne Muscular Dystrophy (DMD) is significant. The termination of clinical trials investigating the phosphodiesterase inhibitors, sildenafil and tadalafil (which prolong the second messenger molecule of nitric oxide (NO) signaling), are prime examples of this. Both attenuated key dystrophic features in the mdx mouse model of DMD yet failed to modulate primary outcomes in clinical settings. We have previously attempted to modulate NO signaling via chronic nitrate supplementation of the mdx mouse but failed to demonstrate beneficial modulation of key dystrophic features (i.e., metabolism). Instead, we observed increased muscle damage and nitrosative stress which exacerbated MD. Here, we highlight that acute nitrite treatment of human DMD myoblasts is also detrimental and suggest strategies for moving forward with NO replacement therapy in DMD. View Full-Text
Keywords: Duchenne muscular dystrophy; metabolism; nitric oxide; nitrite; reactive oxygen species; superoxide Duchenne muscular dystrophy; metabolism; nitric oxide; nitrite; reactive oxygen species; superoxide
Show Figures

Graphical abstract

MDPI and ACS Style

Timpani, C.A.; Mamchaoui, K.; Butler-Browne, G.; Rybalka, E. Nitric Oxide (NO) and Duchenne Muscular Dystrophy: NO Way to Go? Antioxidants 2020, 9, 1268. https://doi.org/10.3390/antiox9121268

AMA Style

Timpani CA, Mamchaoui K, Butler-Browne G, Rybalka E. Nitric Oxide (NO) and Duchenne Muscular Dystrophy: NO Way to Go? Antioxidants. 2020; 9(12):1268. https://doi.org/10.3390/antiox9121268

Chicago/Turabian Style

Timpani, Cara A., Kamel Mamchaoui, Gillian Butler-Browne, and Emma Rybalka. 2020. "Nitric Oxide (NO) and Duchenne Muscular Dystrophy: NO Way to Go?" Antioxidants 9, no. 12: 1268. https://doi.org/10.3390/antiox9121268

Find Other Styles
Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Article Access Map by Country/Region

1
Back to TopTop